US and adnexal pathology; looking at it the wrong way around (Reply) by Timmerman, Dirk et al.
Accepted Manuscript
Ultrasound and adnexal pathology: what is the evidence?
Wouter Froyman, MD, Lil Valentin, MD, PhD, Dirk Timmerman, MD, PhD
PII: S0002-9378(16)30461-6
DOI: 10.1016/j.ajog.2016.07.027
Reference: YMOB 11224
To appear in: American Journal of Obstetrics and Gynecology
Received Date: 27 June 2016
Accepted Date: 11 July 2016
Please cite this article as: Froyman W, Valentin L, Timmerman D, Ultrasound and adnexal pathology:
what is the evidence?, American Journal of Obstetrics and Gynecology (2016), doi: 10.1016/
j.ajog.2016.07.027.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Ultrasound and adnexal pathology: what is the evidence? 
Wouter FROYMAN, MD1,2, Lil VALENTIN, MD, PhD3, Dirk TIMMERMAN, MD, PhD1,2 
 
 
 
1 KU Leuven, Department of Development and Regeneration, Leuven, Belgium; 2 Department of 
Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; 3 Department of 
Obstetrics and Gynecology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden 
 
 
Conflicts of Interest 
All authors declare: no support from any organization for the submitted work; no financial 
relationships with any organizations that might have an interest in the submitted work in the 
previous three years; no other relationships or activities that could appear to have influenced 
the submitted work. 
 
Corresponding author: 
Dirk Timmerman, MD PhD 
KU Leuven, Department of Development and Regeneration, Leuven, Belgium; Department of 
Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium 
Address:  
Department of Obstetrics and Gynecology,  
University Hospitals Leuven 
Herestraat 49 
3000 Leuven 
Belgium 
tel. +32 16 3 44201 or +32 16 3 44216 
fax +32 16 3 44205 
email: dirk.timmerman@uzleuven.be 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Amor et al. suggest that all adnexal masses should be evaluated by an expert ultrasound 
examiner, because this ultrasound method results in a correct diagnosis of malignancy with a 
specific presumed histology in many cases.  
Because an expert is not always available, we have developed methods intended for use by non-
expert ultrasound examiners to help them correctly classify adnexal masses as being malignant 
or benign. One of these methods is the Simple Rules Risk system.1 The ultrasound features used 
in this model are the same as those used in the Simple Rules, which perform well in the hands of 
non-experts.2 Therefore, the Simple Rules Risk system is likely to perform equally well in the 
hands of non-expert users. 
We agree that it is not necessary to apply risk prediction models to all adnexal masses, because 
many tumors exhibit characteristic ultrasound features which make them easy to recognize. 
This strategy corresponds to our Easy Descriptors, which can be used by examiners with limited 
ultrasound experience.2 The statement by Amor et al. that the Easy Descriptors have an accuracy 
of 43% is incorrect. When used by non-experts they were applicable in 46% of tumors and when 
applicable they had 93% sensitivity and 97% specificity.2 A strategy of first using the Easy 
Descriptors and then using a risk prediction model such as the Simple Rules Risk system as a 
second step has good diagnostic performance.3 
It is surprising that Amor et al. criticize our risk prediction model, because their own 
Gynecological Imaging Reporting and Data System (GI-RADS) is based on the estimated risk of 
malignancy. For example, their study includes 184 GI-RADS grade 3 patients (with an estimated 
risk of malignancy of 1-4%), of whom 182 underwent surgery to detect only one case of 
malignancy.4 To the best of our knowledge, GI-RADS has not been tested in the hands of non-
experts.  
In the ongoing IOTA phase 5 study we investigate the behavior of adnexal masses in long-term 
follow-up, including the risk of complications. Only when the results of this study are available, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
an algorithm for clinical management of all types of adnexal pathology can be developed. Once 
taken up by (inter)national guidelines, this should result in a reduced number of surgical 
procedures for benign disease (and the entailed risks and costs) and appropriate referral to 
gynecological oncologists in case of malignant disease.  
 
WORD COUNT: 389 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
References 
1. Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal 
masses based on the Simple Rules from the International Ovarian Tumor Analysis (IOTA) 
group. Am J Obstet Gynecol 2016;214(4),424-437.  
2. Sayasneh A, Kaijser J, Preisler J, et al. A multicenter prospective external validation of the 
diagnostic performance of IOTA simple descriptors and rules to characterize ovarian 
masses. Gynecol Oncol 2013;130(1):140-146.  
3. Froyman W, Landolfo C, Bourne T, et al. Performance of the RMI and IOTA ADNEX and 
Simple Rules risk model in the evaluation of adnexal masses not classifiable using the 
Easy Descriptors as first step, Dame Hilda Lloyd Medal – Plenary Session (PFC). BJOG: Int 
J Obstet Gyn 2016;123:83–84. doi:10.1111/1471-0528.14098 
4. Amor F, Alcázar JL, Vaccaro H, León M, Iturra A. GI-RADS reporting system for ultrasound 
evaluation of adnexal masses in clinical practice: a prospective multicenter study. 
Ultrasound Obstet Gynecol 2011;38:450–455. 
